For Healthcare Professionals Outside the US
US Residents | Summary of Product Characteristics: Tafinlar Mekinist | Safety Information
For adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.
Choose Tafinlar + Mekinist to reduce your adjuvant patients’ risk of relapse and protect their QOL1,3,6
Nearly 1 in 5 patients with metastatic melanoma achieved a complete response with Tafinlar + Mekinist in the Phase III COMBI-v clinical trial4
Tafinlar + Mekinist is the first and only approved targeted therapy to treat adult patients with BRAF V600+ NSCLC1,2
OS, overall survival; QOL, quality of life.
References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2018. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2018. 3. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823. 4. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. 5. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Abstract presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. 6. Data on file. Novartis Pharmaceuticals Corp; 2018.
Privacy Site Map Contact Us Summary of Product Characteristics: Tafinlar Mekinist Safety Information
Disclaimer: This is an international site for Tafinlar® (dabrafenib) + Mekinist® (trametinib) and is intended for healthcare professionals outside the US. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local representative for local prescribing information via www.novartisoncology.com/contact-novartis-oncology.jsp.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)
© 2019 Novartis AG Use of this website is subject to our Terms of Use